Variant: rs121913459 

    present in Gene: ABL1
    present in Chromosome: 9
    Position on Chromosome: 130872896
    Alleles of this Variant: C/T

rs121913459 in ABL1 gene and Acute lymphoblastic leukemia with lymphomatous features PMID 11861307 2002 Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 22772060 2013 MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

rs121913459 in ABL1 gene and Myeloid Leukemia, Chronic PMID 24236021 2013 Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.

PMID 11423618 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.

PMID 21762985 2011 Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

PMID 21562040 2011 BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

PMID 20512393 2011 The mutation status of 65 patients with resistant CML was evaluated, and the T315I was detected in 3/65 (4.6%).

PMID 22306673 2012 Rapid quantitative detection of the T315I mutation in patients with chronic myelogenous leukemia.

PMID 23355941 2012 Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.

PMID 15194504 2004 The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase.

PMID 22870928 2013 Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction.

PMID 20537386 2010 BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

PMID 21872826 2011 Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.

PMID 11964322 2002 High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

PMID 21895409 2011 Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.

PMID 12399961 2002 Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.

PMID 12130516 2002 Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

PMID 14745431 2004 High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

PMID 12623848 2003 Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.

PMID 20963643 2010 We report a chronic-phase CML patient undergoing IM treatment, who showed the overt existence of the T315I mutation after 15 months.

PMID 11853795 2002 BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study.

PMID 20367437 2010 Mutations in ABL kinase domain are associated with inferior progression-free survival.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 23676790 2013 Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.

PMID 23540562 2013 In the present study, an allele-specific oligonucleotide reverse transcriptase polymerase chain reaction assay was used to detect T315I mutation in a cohort of 60 imatinib-resistant CML patients.